📈 Live Market Tracking
AI-Powered NSE Corporate Announcements Analysis
Supriya Lifescience Q3 FY26: Revenue Grows 11% to ₹206 Cr, Maintains 20% Growth Guidance
Supriya Lifescience reported a steady Q3 FY26 with revenue increasing 11% YoY to ₹206 crores and a PAT of ₹50 crores. The company maintained a strong EBITDA margin of 34.9%, supported by high-margin niche products and an 82% export contribution. Management reaffirmed its 20% annual revenue growth guidance and the ₹1,000 crore revenue milestone target for FY27. Key growth drivers include the launch of cardiovascular and ADHD products and the upcoming capitalization of the Ambernath facility in Q4 FY26.
Key Highlights
Q3 FY26 revenue rose 11% YoY to ₹206 crores with an EBITDA margin of 34.9% (₹72 crores).
Exports contributed 82% of total revenue, led by LatAm (24%) and North America (6%).
Ambernath facility is ready for capitalization in Q4 FY26, which is a key milestone for the CDMO segment.
Management maintains FY26 guidance of 20% revenue growth and 33-35% EBITDA margins.
Backward integration initiatives supported 74% of revenues, strengthening the overall cost structure.
💼 Action for Investors
Investors should monitor the scale-up of new cardiovascular and ADHD products in Q4, which are expected to drive the guided 20% annual growth. The capitalization of the Ambernath facility remains a key trigger for the expansion of the CDMO business.
Supriya Lifescience Q3 FY26 Revenue Up 11.2% YoY to ₹206.4 Cr; PAT at ₹49.7 Cr
Supriya Lifescience reported a steady 11.2% YoY revenue growth for Q3 FY26, reaching ₹206.44 crore, driven by strong demand in the anesthetic segment and expansion in Latin American markets. While EBITDA grew by 9.3% to ₹72.08 crore, margins saw a slight contraction to 34.9% from 35.5% in the previous year. Net profit increased by 6.2% YoY to ₹49.68 crore, supported by a high export contribution of 82%. The company is preparing for the commercial launch of its Ambernath formulation facility in Q4 FY26 and has acquired land for future expansion.
Key Highlights
Revenue grew 11.2% YoY to ₹206.44 crore, while PAT increased 6.2% to ₹49.68 crore.
Anesthetic segment contribution rose to 54% of total revenues in 9M FY26 from 48% YoY.
Capacity utilization improved to 76% in 9M FY26, up from 70% in the previous fiscal year.
Geographic diversification improved with North America share doubling to 6% and LatAm rising to 24%.
Acquired three new land parcels and scheduled Ambernath facility launch for Q4 FY26.
💼 Action for Investors
Investors should monitor the successful commissioning of the Ambernath facility in Q4 FY26 as a key growth catalyst. The stock remains attractive due to high margins and strong export presence, though margin stabilization should be watched.
Supriya Lifescience Q3 FY26 Revenue Up 11.2% YoY to ₹2,064 Mn; PAT Grows 6.2%
Supriya Lifescience reported a steady performance for Q3 FY26, with revenue from operations growing 11.2% YoY to ₹2,064.4 million. While EBITDA increased by 9.3% to ₹720.8 million, margins saw a slight compression of 61 bps to 34.9% due to higher employee and other expenses. The company continues to strengthen its backward integration, which now accounts for 74% of 9M FY26 revenue. Key growth drivers include the expansion into Liquid Anesthesia and the upcoming commissioning of the Ambernath FDF facility in H2 FY26.
Key Highlights
Revenue from operations grew 11.2% YoY to ₹2,064.4 Mn in Q3 FY26.
EBITDA stood at ₹720.8 Mn with a margin of 34.9%, while PAT grew 6.2% YoY to ₹496.8 Mn.
Anesthetics segment dominated the therapy mix, contributing 54% to 9M FY26 revenue.
Export markets remain strong, contributing 82% of total revenue in Q3 FY26.
Total reactor capacity reached 932 KLPD with the addition of the 335 KLPD Block E.
💼 Action for Investors
Investors should monitor the ramp-up of the newly commissioned Block E and the upcoming Ambernath FDF facility for margin improvement. The company's strong backward integration and leadership in niche APIs provide a competitive moat.
Supriya Lifescience Appoints New Independent Directors and Reconstitutes Board Committees
Supriya Lifescience has strengthened its board by appointing two new Additional Independent Directors, Mr. Manish Panchal and Mr. Kothandaraman Hari, for five-year terms effective February 9, 2026. Mr. Hari brings significant capital markets expertise as a former Executive Vice President at the NSE, while Mr. Panchal offers over 32 years of experience in the chemical and pharma sectors. The company also re-appointed Dr. Neelam Yashpal Arora for a second five-year term as an Independent Woman Director. These appointments coincide with the approval of the unaudited financial results for the quarter ended December 31, 2025.
Key Highlights
Appointment of Mr. Kothandaraman Hari (former NSE EVP) as Additional Independent Director for a 5-year term.
Appointment of Mr. Manish Panchal (Business Leader with 32+ years experience) as Additional Independent Director for a 5-year term.
Re-appointment of Dr. Neelam Yashpal Arora as Independent Woman Director for a second term from 2026 to 2031.
Reconstitution of the Audit, Nomination and Remuneration, and Stakeholders’ Relationship Committees.
Board approval of unaudited financial results for the quarter and nine months ended December 31, 2025.
💼 Action for Investors
Investors should view the addition of a capital markets veteran and a strategy expert to the board as a positive step for corporate governance. While the management changes are routine, shareholders should focus on the Q3 FY26 financial results to assess the company's current growth trajectory.
Supriya Lifescience Appoints Former NSE EVP to Board; Approves Q3 FY26 Results
Supriya Lifescience has approved its unaudited financial results for the quarter ended December 31, 2025, alongside significant board-level appointments. The company has inducted Mr. Kothandaraman Hari, a former Executive VP at the National Stock Exchange (NSE) with 28 years of experience, and Mr. Manish Panchal, a veteran in the pharma and chemical sectors, as Independent Directors. Additionally, Dr. Neelam Yashpal Arora was re-appointed for a second five-year term. These moves, including the reconstitution of key board committees, signal a strong push toward enhanced corporate governance and strategic oversight.
Key Highlights
Approved unaudited financial results for the quarter and nine months ended December 31, 2025.
Appointed Mr. Kothandaraman Hari, a capital markets veteran and former NSE Executive VP, as an Independent Director for 5 years.
Appointed Mr. Manish Panchal, with 32+ years of experience in Chemicals and Pharma, as an Additional Independent Director.
Re-appointed Dr. Neelam Yashpal Arora as Independent Woman Director for a second 5-year term effective March 2026.
Reconstituted the Audit, Nomination & Remuneration, and Stakeholders’ Relationship Committees with new independent leadership.
💼 Action for Investors
The addition of a high-profile capital markets veteran from the NSE to the board is a positive indicator for corporate governance and institutional credibility. Investors should view these leadership changes as a strategic move to strengthen the company's market positioning and compliance framework.
Supriya Lifescience Appoints New Independent Directors and Approves Q3 FY26 Results
Supriya Lifescience's board met on February 09, 2026, to approve the unaudited financial results for the quarter ended December 31, 2025. The company announced the re-appointment of Dr. Neelam Yashpal Arora and the induction of two new independent directors, Mr. Manish Panchal and Mr. Kothandaraman Hari, for five-year terms. Mr. Hari brings significant capital markets expertise from his 28-year tenure at the National Stock Exchange (NSE). These appointments aim to strengthen corporate governance and strategic oversight as the company reconstitutes its key board committees.
Key Highlights
Approved unaudited financial results for the quarter and nine months ended December 31, 2025.
Appointed Mr. Kothandaraman Hari, former Executive VP at NSE, as an Additional Independent Director for a 5-year term.
Appointed Mr. Manish Panchal, a business leader with 32+ years of experience in Chemicals and Pharma, as an Additional Independent Director.
Re-appointed Dr. Neelam Yashpal Arora as Independent Woman Director for a second 5-year term starting March 2026.
Reconstituted the Audit, Nomination & Remuneration, and Stakeholders’ Relationship Committees with new independent members.
💼 Action for Investors
Investors should review the detailed Q3 FY26 financial statements to assess the company's growth trajectory. The addition of high-caliber professionals from the NSE and the pharma industry to the board is a positive sign for governance and strategic planning.
Supriya Lifescience Assigned IND A+/Positive Rating for Rs 1,140 Cr Bank Facilities
India Ratings and Research (Ind-Ra) has assigned credit ratings to Supriya Lifescience Limited's bank loan facilities totaling Rs. 1,140 crore. The company received a long-term rating of 'IND A+' with a 'Positive' outlook and a short-term rating of 'IND A1'. This assignment indicates a strong credit profile and the 'Positive' outlook suggests potential for future upgrades. The rating reflects the company's ability to manage its significant banking facilities effectively.
Key Highlights
India Ratings and Research assigned ratings to bank loan facilities worth Rs. 1,140 crore
Long-term rating assigned as 'IND A+' with a 'Positive' outlook
Short-term rating assigned as 'IND A1' for the specified facilities
The rating action was officially communicated on December 30, 2025
💼 Action for Investors
The positive outlook and strong credit ratings are favorable indicators of financial health and may lead to lower borrowing costs. Investors should monitor the company's execution to see if the positive outlook leads to a rating upgrade in the future.